TrkA Overview
Molecule Name
Nerve growth factor receptor Trk-A
Synonyms
TrkA,NTRK1,MTC,TRK,TRKA,Trk-A
Drug Development Progress
Drugs in Clinical Trials24
Approved Drugs5
Highest Development StageApproved
Target Synonym
P140-TrkA，Gp140trk，MTC，TRK，Oncogene TRK，EC 2.7.10.1，TRK1，Receptor， trkA，High Affinity Nerve Growth Factor Receptor，Tropomyosin-Related Kinase A，TRKA，Trk-A，Tyrosine kinase receptor，Neurotrophic Receptor Tyrosine Kinase 1，Neurotrophic Tyrosine Kinase， Receptor， Type 1，EC 2.7.10，EC:2.7.10.1，NTRK1，Neurotrophic tyrosine kinase receptor type 1，TRK1-transforming tyrosine kinase protein，Tyrosine kinase receptor A
Background
Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand. Can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 but has no effect on neuron survival. Upon dimeric NGF ligand-binding, undergoes homodimerization, autophosphorylation and activation. Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation. In absence of ligand and activation, may promote cell death, making the survival of neurons dependent on trophic factors.
TrkA Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Tavilermide | MIM-D3; NMG938VJ6T (UNII code) | Phase 3 Clinical | Mimetogen Pharmaceuticals | Dry Eye Syndromes; Keratoconjunctivitis Sicca; Xerophthalmia | Details |
| Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd | Bone Marrow Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neuroblastoma; Polycythemia Vera; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Prostatic Neoplasms; Psoriasis; Thrombocythemia, Essential | Details |
| SNA-125 | CT-340; SNA-125 | Phase 2 Clinical | Creabilis Sa, Sienna Biopharmaceuticals Inc | Dermatitis, Atopic; Pruritus; Psoriasis | Details |
| OPN-7486 | PLX-7486; PLX7486-TsOH | Phase 2 Clinical | Plexxikon Inc | Giant Cell Tumor of Tendon Sheath; Neoplasms; Solid tumours | Details |
| Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours | Details |
| Milciclib maleate | PHA-848125; TZLS-201; PHA-848125C; PHA-125; PHA-848125AC | Phase 2 Clinical | Nerviano Medical Sciences Srl, Tiziana Life Sciences Plc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Solid tumours; Thymoma | Details |
| FCN-011 | FCN-011 | Phase 2 Clinical | Solid tumours | Details | |
| Recombinant human nerve growth factor (Xintrum Pharmacouticals) | rh-NGF; ZX1305; ZX-1305; ZX1305E; ZX-1305-E | Phase 2 Clinical | Jiangsu Zhongxin Pharmaceutical Co Ltd | Glaucoma, Open-Angle; Keratitis; Optic Nerve Injuries | Details |
| AK-1830 | AK-1830; ARRY-954 | Phase 2 Clinical | Array Biopharma | Low Back Pain | Details |
| CNTX-0066 | CNTX-0066 | Phase 2 Clinical | Centrexion Therapeutics Corp | Osteoarthritis, Knee | Details |
| STSP-0902 | STSP-0902; STSP0902 | Phase 2 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Asthenozoospermia; Keratitis; Neurotrophic Keratitis; Oligospermia | Details |
| BEN-2293 | BEN-00002293; BEN-2293 | Phase 2 Clinical | Benevolentai Bio Ltd | Dermatitis, Atopic | Details |
| VMD-928 | VMD-928 | Phase 2 Clinical | Vm Oncology Llc | Carcinoma, Adenoid Cystic; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Laryngeal Neoplasms; Lung Neoplasms; Mesothelioma; Pancreatic Neoplasms; Salivary Gland Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| Emzeltrectinib | CT-3417; TQB-3558 | Phase 1 Clinical | Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Solid tumours | Details |
| BPI-28592 | BPI-28592 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Neoplasm Metastasis; Solid tumours | Details |
| ACD-856 | ACD-856 | Phase 1 Clinical | Alzecure Pharma Ab | Alzheimer Disease; Cognition Disorders | Details |
| HG-030 | HG-030 | Phase 1 Clinical | Hitgen Inc | Solid tumours | Details |
| CSCJC-3456 | CSCJC3456; CSCJC-3456 | Phase 1 Clinical | Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co Ltd, Hebei Changshan Biochemical Pharmaceutical Co Ltd | Solid tumours | Details |
| BR-01T | BR01T; BR-01T | Phase 1 Clinical | Xiyuan Anjian Pharmaceutical (Shanghai) Co Ltd | Low Back Pain | Details |
| HT006.2.2 | HT006.2.2; HT-006.2.2 | Phase 1 Clinical | Wuhan Hiteck Biological Pharma Co Ltd | Keratitis | Details |
| T-1301 | T-1301; DBPR-216; BPR-1J481; BPR1J481 | Phase 1 Clinical | Taivex Therapeutics Corp | Lymphoma; Solid tumours | Details |
| Paltimatrectinib | PBI-200 | Phase 1 Clinical | Pyramid Biosciences | Brain Neoplasms; Desmoplastic Small Round Cell Tumor; Solid tumours | Details |
| FCN-098 | FCN-098; FCN098 | Phase 1 Clinical | Neoplasms; Solid tumours | Details | |
| E-2511 | E2511; E-2511 | Phase 1 Clinical | Eisai Inc | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Taletrectinib Adipate | DS-6051b; DS-6051a; DS-6051; AB-106; IBI-344 | Approved | Daiichi Sankyo Co Ltd | 达伯乐, DOVBLERON, IBTROZI | Mainland China | Carcinoma, Non-Small-Cell Lung | AnHeart Therapeutics Co Ltd | 2024-12-17 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Neoplasms; Solid tumours | Details |
| Entrectinib | NMS-E628; RXDX-101; RG-6268 | Approved | Nerviano Medical Sciences Srl | Rozlytrek, 罗圣全 | Japan | Carcinoma, Non-Small-Cell Lung | Chugai Pharmaceutical Co Ltd | 2019-06-18 | Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Lymphoproliferative Disorders; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Sarcoma; Solid tumours; Thyroid Cancer, Papillary | Details |
| Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Adenocarcinoma; Adenoma; Bile Duct Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastrinoma; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glucagonoma; Hemangiosarcoma; Insulinoma; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Melanoma; Meningioma; Neoplasm Metastasis; Neoplasms; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Sarcoma; Sarcoma, Ewing; Solid tumours; Somatostatinoma; Stomach Neoplasms; Thymoma; Thyroid Neoplasms | Details |
| Larotrectinib sulfate | LOXO-101; ARRY-470; BAY-2757556 | Approved | Array Biopharma | Vitrakvi, 维泰凯 | United States | Solid tumours | Bayer Healthcare | 2018-11-26 | Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Ependymoma; Esophageal Neoplasms; Fibrosarcoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hepatoblastoma; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Leukemia; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Medulloblastoma; Melanoma; Multiple Myeloma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Wilms Tumor; Xanthogranuloma, Juvenile | Details |
| Repotrectinib | TPX-0005; BMS-986472; ZL-2308 | Approved | Turning Point Therapeutics Inc | Augtyro, 奥凯乐 | United States | Carcinoma, Non-Small-Cell Lung | Bristol-Myers Squibb Company | 2023-11-15 | Brain metastases; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Hepatic Insufficiency; Lymphoma; Neoplasms; Solid tumours | Details |